|
Match
|
Document |
Document Title |
|
|
7541440 |
Chimeric, human and humanized anti-granulocyte antibodies and methods of use
The present invention provides humanized, chimeric and human MN3 antibodies, fusion proteins, and fragments thereof. The antibodies, fusion proteins, and fragments thereof, as well as combinations...
|
|
|
7541033 |
Humanized anti-IL-1β antibodies
The present invention encompasses isolated antibodies, or antigen-binding portions thereof, that specifically bind mature human IL-1 Beta. These antibodies, or antigen-binding portions thereof,...
|
|
|
7541441 |
Antibodies that specifically bind to TL5
The present invention relates to antibodies and related molecules that specifically bind to TL5. Such antibodies have uses, for example, in the prevention and treatment of cancer as well as immune...
|
|
|
7541443 |
Anti-CD4 antibodies
Inducing tolerance in a primate by use of a compound, or a combination of at least two compounds, that has certain characteristics when tested in vitro. The compound, alone or in combination, is...
|
|
|
7537757 |
Methods of facilitating vascular growth in cardiac muscle and methods for the production of recombinant EMAP II
A method of facilitating vascular growth in cardiac muscle of a subject in need of such treatment comprises inhibiting EMAP II activity in said subject by an amount effective to stimulate vascular...
|
|
|
7538196 |
Bispecific antibody molecule
A first bispecific antibody molecule comprises at least one binding site with a variable domain on a light chain (V L ) and a variable domain for the T-cell receptor CD-28, linked thereto on a...
|
|
|
7537760 |
Monoclonal antibodies recognizing BAG3 protein sequences and their use in diagnostic and therapy of cell death-involving diseases
The present invention provides BAG3 nucleotide and protein sequences to be used in research, diagnostics and therapy for modulation of cell survival and/or death, in particular in leukemias, other...
|
|
|
7537763 |
Anti-CD40 monoclonal antibody
An antibody or a functional fragment thereof, acting agonistically or antagonistically on CD40.
|
|
|
7537931 |
Humanized anti-ERBB2 antibodies and treatment with anti-ERBB2 antibodies
The present application describes humanized anti-ErbB2 antibodies and methods for treating cancer with anti-ErbB2 antibodies, such as humanized anti-ErbB2 antibodies.
|
|
|
7538195 |
Anti-IGF-I receptor antibody
Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of these molecules with cytotoxic agents, which specifically bind to and inhibit...
|
|
|
7534440 |
Fusion molecules and methods for treatment of immune diseases
The invention concerns bifunctional fusion molecules, and novel, safer and more efficacious methods for the treatment of immune disorders resulting from excessive or unwanted immune responses. The...
|
|
|
7534866 |
Methods and compositions for generating bioactive assemblies of increased complexity and uses
The present invention concerns methods and compositions for making and using bioactive assemblies of defined compositions, which may have multiple functionalities and/or binding specificities. In...
|
|
|
7534431 |
Methods and compositions for administering therapeutic and diagnostic agents
Methods and compositions are described for targeting therapeutic and diagnostic molecules to particular types of cells using targeting antibodies or other targeting moeities.
|
|
|
7534428 |
Antibodies to tumor necrosis factor receptors 6α and 6β
The present invention relates to novel Tumor Necrosis Factor Receptor proteins. In particular, isolated nucleic acid molecules are provided encoding the human TNFR-6α & -6β proteins. TNFR-6α &...
|
|
|
7531168 |
Method for downmodulating immune response in type I diabetes
The instant invention provides compositions and methods for downmodulation of immune responses, e.g., autoimmune responses. For example, methods of downmodulating an immune response using agents...
|
|
|
7531637 |
IL-31 monoclonal antibodies
The present invention relates to methods of treating pruritic diseases, including but not limited to Contact dermatitis, Atopic Dermatitis, Drug induced delayed type cutaneous allergic reactions,...
|
|
|
7531633 |
Staphylococcus antibodies
A negatively-charged Staphylococcus antigen contains amino acids and a N-acetylated hexosamine as a major carbohydrate component. The antigen is common to many coagulase-negative strains of ...
|
|
|
7531175 |
Methods for modulation of immune responses using humanized immunoglobulins reactive with B7-1 molecules
The invention relates to humanized anti-B7-2 and anti-B7-1 antibodies, wherein each comprise a variable region of non-human origin and at least a portion of an immunoglobulin of human origin. The...
|
|
|
7531645 |
Protein purification
A method for purifying a polypeptide by ion exchange chromatography is described which involves changing the conductivity and/or pH of buffers in order to resolve a polypeptide of interest from one...
|
|
|
7531178 |
Immunoadhesin comprising a glycoprotein VI domain
The present invention provides a fusion protein comprising (1) the extracellular domain of glycoprotein VI or a variant thereof that is functional for binding to collagen and (b) the Fc domain of...
|
|
|
7531171 |
Antibodies to non-functional P2X7 receptor
The present invention provides antibodies that specifically bind to P2X 7 receptors and distinguish between function and non-functional P2X 7 receptors, pharmaceutical compositions and kits...
|
|
|
7531636 |
Antibodies to murine zcytor17 ligand
The present invention relates to zcytor17lig polynucleotide, polypeptide and anti-zcytor17 antibody molecules. The zcytor17lig is a novel cytokine. The polypeptides may be used within methods for...
|
|
|
7528236 |
Humanized anti-beta7 antagonists and uses therefor
The invention provides therapeutic anti-beta7 antibodies, compositions comprising, and methods of using these antibodies.
|
|
|
7528111 |
Method of vaccinating subjects receiving immune modulating therapy
The present invention relates to methods of vaccinating subjects receiving immune modulating therapy, such as soluble CTLA4 molecules, for treatment of immune system diseases mediated by T-cell...
|
|
|
7527972 |
Uses of bispecific antibody coated dendritic cells pulsed with antigens and GM-CSF in immune regulation
GM-CSF administered before immunization exerted a sustained suppressive effect against the induction of myasthenia gravis (MG). This suppression was associated with lowered serum autoantibody...
|
|
|
7527790 |
Methods of reducing bone absorption comprising administering an antibody that binds OBM
Novel proteins and polypeptides binding to osteoclastogenesis inhibitory factor (OCIF) (OCIF-binding molecules, OBMs) and nucleic acids encoding these proteins and polypeptides are provided....
|
|
|
7527787 |
Multivalent immunoglobulin-based bioactive assemblies
The present invention concerns methods and compositions for stably tethered structures of defined compositions, which may have multiple functionalities and/or binding specificities. Preferred...
|
|
|
7524498 |
Human immunomodulatory monoclonal antibodies for the treatment of cancer
The present invention provides to a humanized monoclonal antibody having immunostimulatory effects. This antibody binds specifically to B lymphoblastoid cells, induces proliferation and activation...
|
|
|
7521532 |
GL50 polypeptides
The invention provides isolated nucleic acids molecules, designated GL50 nucleic acid molecules, which encode novel GL50 polypeptides. The invention also provides antisense nucleic acid molecules,...
|
|
|
7521055 |
Ferroportin1 antibodies and methods
Positional cloning has been carried out to identify the gene responsible for the hypochromic anemia of the zebrafish mutant weissherbst. The gene, ferroportin1, encodes a novel...
|
|
|
7521539 |
Anti-PRO4989 antibodies
The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid...
|
|
|
7521542 |
Humanized FcγRIIB-specific antibodies and methods of use thereof
The present invention relates to humanized FcγRIIB antibodies, fragments, and variants thereof that bind human FcγRIIB with a greater affinity than said antibody binds FcγRIIA. The invention...
|
|
|
7521056 |
Stably tethered structures of defined compositions with multiple functions or binding specificities
The present invention concerns methods and compositions for stably tethered structures of defined compositions with multiple functionalities and/or binding specificities. Particular embodiments...
|
|
|
7517965 |
Non-neutralizing anti-aPC antibodies
The present invention provides anti-aPC antibodies that suppress the inactivation of activated protein C (aPC), and uses thereof. The present inventors screened anti-aPC antibodies, and succeeded...
|
|
|
7517963 |
Tumour necrosis factor binding ligands
The present invention relates to ligands which bind to human tumor necrosis factor alpha (TNF) in a manner such that upon binding of these ligands to TNF the biological activity of TNF is modified....
|
|
|
7517524 |
Immunointeractive molecules
The present invention relates generally to immunointeractive molecules and more particularly antibodies which bind to vascular endothelial growth factor-B (VEGF-B) or its functional or structural...
|
|
|
7517523 |
Anti-MIF antibodies
The present invention relates to compositions and methods for inhibiting the release and/or biological activity of migration inhibitory factor (MIF). In particular, the invention relates to the...
|
|
|
7517958 |
Interleukin-17 receptor homologue
Cytokines and their receptors have proven usefulness in both basic research and as therapeutics. The present invention provides a new human cytokine receptor designated as “Zcytor14.”
|
|
|
7514239 |
Nucleic acid molecules encoding beta-like glycoprotein hormone polypeptides and heterodimers thereof
Novel β10 polypeptides and heterodimers thereof, and nucleic acid molecules encoding the same are disclosed. The invention also provides vectors, host cells, selective binding agents, and methods...
|
|
|
7514079 |
Antibodies that specifically bind to neurokinin B
The present invention relates to antibodies and related molecules that specifically bind to neurokinin B. Such antibodies have uses, for example, in the prevention and treatment of cancer as well...
|
|
|
7514538 |
Compositions and methods for the diagnosis and treatment of tumor
The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.
|
|
|
7514534 |
Metalloproteinase-binding proteins
Disclosed are antibodies that interact with a matrix metalloproteases such as MMP-26. Exemplary antibodies inhibit MMP-26 activity. These antibodies can be used, e.g., to treat or prevent...
|
|
|
7514078 |
Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
Modified antibodies, or antigen-binding fragments thereof, to the extracellular domain of human prostate specific membrane antigen (PSMA) are provided. The modified anti-PSMA antibodies, or...
|
|
|
7514539 |
Epitope directed selection of antibodies to murine tissue factor
A tissue factor antibody which binds to non-human tissue factor and is useful as a surrogate in preclinical testing where the human therapeutic tissue factor candidate antibody does not interact...
|
|
|
7514537 |
Chimeric immunoreceptor useful in treating human gliomas
The present invention relates to chimeric transmembrane immunoreceptors, named “zetakines,” comprised of an extracellular domain comprising a soluble receptor ligand linked to a support region...
|
|
|
7510840 |
Method of inhibiting growth or survival of a cell by providing an anti-108P5H8 antibody
A novel gene (designated 108P5H8) and its encoded protein, and variants thereof, are described wherein 108P5H8 exhibits tissue specific expression in normal adult tissue, and is aberrantly...
|
|
|
7510712 |
Methods of treating rheumatoid arthritis with 7C10 and 16C10 CD80-specific antibodies
The present invention relates to the identification of antibodies which are specific to human B7.1 antigen (CD80) and which are capable of inhibiting the binding of B7.1 to a CD28 receptor and...
|
|
|
7511122 |
Humanized and chimeric antibodies specific for lipoteichoic acid of GRAM positive bacteria
The present invention encompasses monoclonal and chimeric antibodies that bind to lipoteichoic acid of Gram positive bacteria. The antibodies also bind to whole bacteria and enhance phagocytosis...
|
|
|
7510713 |
Methods of inducing immunosuppression by administering 7C10 and 16C10 CD80-specific antibodies
The present invention relates to the identification of antibodies which are specific to human B7.1 antigen (CD80) and which are capable of inhibiting the binding of B7.1 to a CD28 receptor and...
|
|
|
7511123 |
Immuno-interactive fragments of the alpha-C subunit of inhibin
Novels immuno-interactive fragments of the (alpha)C portion of a mammalian inhibin alpha subunit are disclosed, together with their variants and derivatives for producing antigen-binding molecules...
|